White Paper

The Future of Pharmacovigilance: How COVID-19 Has Inspired Innovation

By Annette Williams, R.Ph, Vice President and Global Head of Lifecycle Safety, IQVIA, and Barry Mulchrone, Senior Director and Head of Pharmacovigilance Oversight and Analytics

iStock-1127257350-innovation-ideas-lightbulb

As with many areas of the pharmaceutical industry, COVID-19 created significant disruption for pharmacovigilance (PV) activities, including post-marketing surveillance. The rapidly growing volume of data along with shifting regulatory and consumer trends due to the pandemic, forced leaders to rethink their typical safety data management processes and PV technology, in order to bring unprecedented levels of scalability, reliability and agility to their workflow. 

IQVIA's Lifecycle Safety and Pharmacovigilance team has been on the front lines of this pandemic from the start, providing support to several customers conducting research into COVID medicines and vaccines, as well as providing global PV support. Discover the challenges to maintaining PV standards and experienced the opportunities to reimagine PV strategies and accelerate the implementation of automation and process changes.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to:

IQVIA Research & Development Solutions